CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Bibliographic Information

Published
2015-06-01
Resource Type
journal article

Journal

Details 詳細情報について

Report a problem

Back to top